Related Experiment Video
Updated: Aug 17, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Stage II endometrial carcinoma: limiting post-operative radiotherapy to the vaginal vault in node-negative tumors
Paula V C Rittenberg1, Robert J Lotocki, Mark S Heywood
1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Dalhousie University, Dickson Building, 5820 University Avenue, Halifax, Nova Scotia, Canada B3H 1V7. paularittenberg@dal.ca
Objective:
To evaluate the outcomes of patients with node-negative stage II endometrial cancer who received vault brachytherapy without external beam pelvic radiotherapy (EBRT).
Methods:
A retrospective review of all stage II endometrioid type endometrial cancer patients referred to Cancer Care Manitoba was undertaken between October 1995 and March 2001. Forty-nine patients were identified with disease confined to the uterus, but not all patients received extended surgical staging (ESS) with pelvic lymphadenectomy. These patients were evaluated for recurrence and morbidity data.
Results:
Twenty node-negative stage II cancers were identified. Three were treated without adjuvant treatment, 12 received vault brachytherapy and 5 received more conventional treatment with EBRT and vault brachytherapy. No recurrences or deaths occurred in these patients. Mean follow-up was 40 months. No surgical complications were encountered in this group and no morbidity from radiotherapy was observed.
Conclusions:
Limiting adjuvant treatment to vault brachytherapy for node-negative stage II endometrial cancer results in less morbidity and excellent survival and is worthy of further investigation.
